Progress and innovation within oncology has accelerated to a paradigm that includes immunotherapy and bio-genomics. Collaborative approaches in the future will continue to transform treatments in hopes of improving patient quality of life.
With significant technology advances in ECG recording through the years, the need to expand on traditional monitoring baselines—and include new variables such as time when designing clinical trial protocols—is important.
This article explores the many challenges to creating a pharmaceutical development program for the treatment of a rare disease.
iCardiac Technologies and SNBL Clinical Pharmacology Center have announced a collaboration on cardiac safety studies in Japan.
Boehringer Ingelheim and the Duke Clinical Research Institute (DCRI) announce the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry.
Quintiles and DaVita Clinical Research have allied to provide capabilities and solutions for renal disease clinical trials.
The Clinical Trials Transformation Initiative (CTTI) have released recommendations for hospital acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as part of its antibacterial drug development program.
eClinicalHealth announced the the final results of the VERKKO remote online Phase IV clinical trial for diabetes.